About ADHD
ADHD is a psychiatric disorder, which is mostly found in children. However, adults have also been reported to be diagnosed with ADHD. The patients with ADHD suffer from several problems including hyperactivity, impulsiveness, and lack of focus and concentration. The causes of ADHD are not known. It is believed to be linked with genetic and environmental causes. However, it has been reported to be related with the decrease in the extraneuronal levels of norepinephrine and dopamine. In addition, the patients have an abnormality in the brain structure. It is more prevalent in boys than girls. The management of ADHD is done by counseling, medications, and lifestyle changes.
TechNavio's analysts forecast the Global ADHD Drugs market to grow at a CAGR of 5.33 percent over the period 2013-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global ADHD Drugs market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various therapies used in the treatment of ADHD, which include:
• Stimulants
• Non-stimulants
TechNavio's report, the Global ADHD Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global ADHD Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
• APAC
• EMEA
Key Vendors
• Eli Lilly and
• Janssen
• Novartis
• Shire
Other Prominent Vendors
• Actavis
• Alcobra
• Amarantus
• Boehringer Ingelheim
• Concordia
• Curemark
• GlaxoSmithKline
• Hisamitsu
• Impax
• Intellipharmaceutics
• Mylan
• Neurovance
• Noven
• Par Pharmaceuticals
• Sanofi
• Shionogi
• Sunovion
• Teva
• Tris Pharma
Market Driver
• Presence of Unmet Need
• For a full, detailed list, view our report
Market Challenge
• Unknown Etiology
• For a full, detailed list, view our report
Market Trend
• Increase in Awareness
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Product Profiles
04.1 Strattera
04.2 Concerta/Ritalin
04.3 Focalin
04.4 Intuniv
04.5 Vyvanse/Elvanse/ Venvanse
05. Market Research Methodology
05.1 Market Research Process
05.2 Research Methodology
06. Introduction
07. Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
07.3 Five Forces Analysis
08. Market Segmentation by Product Type
08.1 Stimulants
08.2 Non-stimulants
09. Market Segmentation by Route of Administration
09.1 Oral
09.2 Transdermal
10. Market Segmentation by Dosage Form
10.1 Solid
10.2 Liquid
11. Geographical Segmentation
11.1 Global ADHD Drugs Market by Geographical Segmentation 2013-2018
11.2 ADHD Drugs Market in Americas
11.2.1 Market Overview
11.2.2 Market Size and Forecast
11.2.3 ADHD Drugs Market in the US
11.3 ADHD Drugs Market in EMEA
11.3.1 Market Overview
11.3.2 Market Size and Forecast
11.3.3 ADHD Drugs Market in Spain
11.4 ADHD Drugs Market in APAC
11.4.1 Market Overview
11.4.2 Market Size and Forecast
11.4.3 ADHD Drugs Market in Japan
12. Key Leading Countries
13. Rate of Incidence and Prevalence
14. Buying Criteria
15. Market Growth Drivers
16. Drivers and their Impact
17. Market Challenges
18. Impact of Drivers and Challenges
19. Market Trends
20. Trends and their Impact
21. Vendor Landscape
21.1 Competitive Scenario
21.1.1 Key News
21.1.2 Mergers and Acquisitions
21.2 Market Share Analysis 2013
21.2.1 Eli Lilly
21.2.2 Janssen
21.2.3 Novartis
21.2.4 Shire
21.3 Other Prominent Vendors
22. Pipeline Portfolio
23. Key Vendor Analysis
23.1 Eli Lilly and Co.
23.1.1 Key Facts
23.1.2 Business Overview
23.1.3 Business Segmentation by Revenue 2013
23.1.4 Business Segmentation by Revenue 2012 and 2013
23.1.5 Sales by Geography
23.1.6 Business Strategy
23.1.7 Key Developments
23.1.8 SWOT Analysis
23.2 Janssen Pharmaceuticals
23.2.1 Key Facts
23.2.2 Business Overview
23.2.3 Product Segmentation
23.2.4 Business Strategy
23.2.5 Recent Developments
23.2.6 SWOT Analysis
23.3 Novartis
23.3.1 Key Facts
23.3.2 Business Overview
23.3.3 Business Segmentation by Revenue 2013
23.3.4 Business Segmentation by Revenue 2012 and 2013
23.3.5 Sales by Geography
23.3.6 Business Strategy
23.3.7 Key Developments
23.3.8 SWOT Analysis
23.4 Shire
23.4.1 Key Facts
23.4.2 Business Overview
23.4.3 Geographical Segmentation by Revenue 2013
23.4.4 Business Strategy
23.4.5 Recent Developments
23.4.6 SWOT Analysis
24. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global ADHD Drugs Market 2013-2018 (US$ billion)
Exhibit 3: Global ADHD Drugs Market by Product Type
Exhibit 4: Global ADHD Drugs Market Segmentation by Product Type 2013
Exhibit 5: Global ADHD Drugs Market by Route of Administration
Exhibit 6: Global ADHD Drugs Market Segmentation by Route of Administration 2013
Exhibit 7: Global ADHD Drugs Market by Dosage Form
Exhibit 8: Global ADHD Drugs Market Segmentation by Dosage Form 2013
Exhibit 9: Global ADHD Drugs Market by Geographical Segmentation 2013
Exhibit 10: ADHD Drugs Market in Americas 2013-2018 (US$ million)
Exhibit 11: ADHD Drugs Market in the US 2013-2018 (US$ million)
Exhibit 12: ADHD Drugs Market in EMEA 2013-2018 (US$ million)
Exhibit 13: ADHD Drugs Market in Spain 2013-2018 (US$ million)
Exhibit 14: ADHD Drugs Market in APAC 2013-2018 (US$ million)
Exhibit 15: ADHD Drugs Market in Japan 2013-2018 (US$ million)
Exhibit 16: Global ADHD Drugs Market Share Analysis 2013
Exhibit 17: Region-wise Sales Comparison of Strattera 2010-2013 (US$ million)
Exhibit 18: YOY Sales Comparison of Strattera 2010-2013 (US$ million)
Exhibit 19: YOY Sales Comparison of Strattera in the US 2010-2013 (US$ million)
Exhibit 20: YOY Sales Comparison of Strattera in ROW 2010-2013 (US$ million)
Exhibit 21: YOY Sales Comparison of Concerta 2007-2013 (US$ million)
Exhibit 22: Region-wise Sales Comparison of Novartis' Focalin and Ritalin 2010-2013 (US$ million)
Exhibit 23: YOY Sales Comparison of Novartis' Focalin and Ritalin 2008-2013 (US$ million)
Exhibit 24: YOY Sales Comparison of Novartis' Focalin and Ritalin in the US 2010-2013 (US$ million)
Exhibit 25: YOY Sales Comparison of Novartis' Focalin and Ritalin in ROW 2010-2013 (US$ million)
Exhibit 26: Sales Comparison of Shire's ADHD Drugs 2009-2013 (US$ million)
Exhibit 27: YOY Sales Comparison of Vyvanse 2008-2013 (US$ million)
Exhibit 28: YOY Sales Comparison of Intuniv 2009-2013 (US$ million)
Exhibit 29: YOY Sales Comparison of Adderall 2008-2013 (US$ million)
Exhibit 30: Late Stage Pipeline Molecules for the Treatment of ADHD
Exhibit 31: Eli Lilly and Co.: Business Segmentation by Revenue 2013
Exhibit 32: Eli Lilly and Co.: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 33: Eli Lilly and Co.: Sales by Geography 2013
Exhibit 34: Janssen Pharmaceuticals: Product Segmentation 2013
Exhibit 35: Novartis AG: Business Segmentation by Revenue 2013
Exhibit 36: Novartis AG: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 37: Novartis AG: Sales by Geography 2013
Exhibit 38: Shire: Geographical Segmentation by Revenue 2013
